1. Homepage
  2. Equities
  3. Korea, republic of
  4. Korea Stock Exchange
  5. Celltrion, Inc.
  6. Company
    A068270   KR7068270008

CELLTRION, INC.

(A068270)
  Report
End-of-day quote Korea Stock Exchange  -  2022-08-15
211000.00 KRW   +1.44%
08/15Infliximab Clinical Trial Updates
AQ
08/09Celltrion Files IND With FDA For Adalimumab Biosimilar
AQ
08/07Celltrion's Net Income Jumps 41.2% in June Quarter
MT
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Celltrion, Inc. is a Korea-based company mainly engaged in the production and sale of biopharmaceuticals. Along with subsidiaries, the Company operates its business through three segments. The Biopharmaceutical segment is involved in the manufacturing and sale of biopharmaceutical products such as multivitamins, blood circulation remedies, blood cancer treatments and breast cancer treatments. The Chemical Pharmaceutical segment is involved in the manufacturing and sale of therapeutic drugs for liver disease under the name of Godex, as well as the treatment of autoimmune diseases under the name of Remsima. The Other segment manufactures and sells other generic drugs. The Company distributes its products within the domestic market and to overseas markets.

Number of employees : 2 207 people.
Sales per Business
20202021Delta
Biopharmaceutical1 689 910.0091.4%1 615 840.0084.5% -4.38%
Chemical Drugs242 337.0013.1%556 711.0029.1% +129.73%
Others2 627.680.1%3 054.440.2% +16.24%
KRW in Million
Sales per region
2021
South Korea1 779 870.0093.1%
United States84 608.904.4%
Asia47 119.202.5%
KRW in Million
Managers
Name Title Age Since
Wu-Sung Ki Chief Executive Officer & Director 60 -
Ho-Seop Lee Finance Director 46 -
Sung-Han Lee Head-Legal & Compliance Support 39 -
Jung-Won Yoon Vice President 55 -
Shin-Jae Jang, Dr. President-Executive Board 59 -
Sang-Joon Lee, Dr. Vice President 54 -
Yoon-Mo Koo Executive Board Member 51 -
Members of the board
Name Title Age Since
Jung-Jin Seo Chairman 64 -
Dong-Il Kim, Dr. Independent Director 63 2008
Joseph Lee Independent Director 64 2008
Gyun-Seok Cho Independent Director 62 2009
Byung-Hoon Jeon Independent Director 64 2014
Jong-Seok Lee, Dr. Independent Director 70 2014
Geun-Young Kim Independent Director 62 -
Dae-Hyeon Yoo Independent Director 63 -
Soon-Woo Lee Independent Director 71 -
Jae-Sik Lee, Dr. Independent Director 64 -
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 140,791,866 105,582,551 75.0% 2,512,503 1.8% 75.0%
Shareholders
NameEquities%
Jung-Jin Seo 31,199,933 22.2%
National Pension Service of Korea 8,813,767 6.26%
Temasek Holdings Pte Ltd. (Investment Management) 6,931,650 4.92%
The Vanguard Group, Inc. 2,740,669 1.95%
Celltrion, Inc. 2,505,883 1.78%
BlackRock Fund Advisors 2,194,152 1.56%
Norges Bank Investment Management 1,199,318 0.85%
Samsung Asset Management Co., Ltd. 885,567 0.63%
BlackRock Advisors (UK) Ltd. 748,517 0.53%
Celltrion Inc. Employee Stock Ownership ASSN. 565,787 0.40%
Holdings
NameEquities%Valuation
CELLTRION PHARM, INC. (A068760) 20,678,107 54.9% 1,348,191,485 USD
CELLTRION, INC. (A068270) 2,505,883 1.78% 366,498,169 USD
BIOTOXTECH CO., LTD. (A086040) 1,631,134 11.1% 10,270,713 USD
Company contact information
Celltrion, Inc.
23 Academy-ro
Yeonsu-gu
Inchon, Incheon 22014

Phone : +82.32.850.5000
Fax : +82.32.850.5040
Web : http://www.celltrion.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of Celltrion, Inc.